Metabolic imaging in the response assessment of patients treated with 223Ra. What should be
Tóm tắt
Từ khóa
Tài liệu tham khảo
Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34:1402–1418
Gillessen S, Attard G, Beer TM et al (2018) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73:178–211
Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223
Crawford ED, Petrylak DP, Shore N et al (2017) The role of therapeutic layering in optimizing treatment for patients with castration-resistant prostate cancer (prostate cancer radiographic assessments for detection of advanced recurrence II). Urology 104:150–159
Evangelista L, Zattoni F, Gutilla A et al (2013) Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 38:305–314
Fanti S, Minozzi S, Castellucci P et al (2016) PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging 43:55–69
von Eyben FE, Kairemo K (2016) Acquisition with (11)C-choline and (18)F fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Ann Nucl Med 30:385–392
National Comprehensive Cancer Network (2017). Prostate cancer (version 2). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Miyazaki KS, Kuang Y, Kwee SA (2015) Changes in skeletal tumor activity on (18)Fcholine PET/CT in patients receiving (223)Radium radionuclide therapy for metastatic prostate cancer. Nucl Med Mol Imaging 49:160–164
García Vicente AM, Soriano Castrejón A, Álvarez Cabellos R (2017) Response assessment of radium-223 treatment. Should a fluorocholine PET/CT be performed? Clin Nucl Med 42:761–765
Modi D, Hwang C, Mamdani H et al (2016) Radium-223 in heavily pretreated metastatic castrate-resistant prostate cancer. Clin Genitourin Cancer 14(373–80):e2
Omlin A, Daugaard G, Peer A et al (2016) Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases: a multicenter analysis. J Clin Oncol 34(suppl 15):5057
Keizman D, Peer A, Neumann A et al (2016) Imaging response during therapy with radium-223 (Ra-223) for castrate resistant prostate cancer with bone metastases. J Clin Oncol 34(suppl 2):282
Jadvar H, Challa S, Quinn DI et al (2015) One-year postapproval clinical experience with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer. Cancer Biother Radiopharm 30:195–199
Keizman D, Fosboel MO, Reichegger H et al (2018) Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database. Prostate Cancer Prostatic Dis (in press)
Nome R, Hernes E, Bogsrud TV et al (2015) Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scand J Urol 49:211e7
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228
Maurer T, Eiber M, Schwaiger M et al (2016) Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 13:226–235
Lecouvet EE, Talbot JN, Messiou C et al (2014) Monitoring the response of bone metastases to treatment with magnetic resonance imaging and nuclear medicine techniques: a review and position statement by the European Organization for Research and Treatment of Cancer imaging group. Eur J Cancer 50:2519–2531
Henriksen G, Fisher DR, Roeske JC et al (2003) Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 44:252–259
Henriksen G, Breistol K, Bruland OS et al (2002) Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 62:3120–3125
Poeppel TD, Handkiewicz-Junak D, Andreeff M et al (2017) EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Molec Imag. https://doi.org/10.1007/s00259-017-3900-4
Etchebehere E, Brito AE, Rezaee A et al (2017) Therapy assessment of bone metastatic disease in the era of 223 radium. Eur J Nucl Med Molec Imag 44(Suppl 1):84–96
Wade AA, Scott JA, Kuter I et al (2006) Flare response in 18F-fluoride ion PET bone scanning. AJR Am J Roentgenol 186:1783–1786
Kairemo K, Joensuu T (2015) Radium-223-dichloride in castration resistant metastatic prostate cancer-preliminary results of the response evaluation using F-18-Fluoride PET/CT. Diagnostics (Basel) 5:413–427